By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Conditions A-Z > Rare cancer > Wilms tumor

Wilms tumor

GMJ
Last updated: 02/06/2026 14:31
By
Prof. Giorgi Pkhakadze
Share
13 Min Read
SHARE
9 min read|1,724 words

What is Wilms tumor?

Wilms tumor, also known as nephroblastoma, is a rare cancer that primarily affects children’s kidneys. It develops from embryonic kidney tissue that fails to mature properly during fetal development. This cancer typically strikes young children, with most cases diagnosed before age 5, though it can rarely occur in older children and adults. Wilms tumor affects approximately 1 in 10,000 children, making it the most common kidney cancer in children despite its rarity.

Key statistics

Prevalence ~1 in 10,000 children
Annual incidence 7-8 cases per million children under 15
Peak age of diagnosis 2-3 years old
5-year survival rate 90-95% with treatment

Symptoms

Common early symptoms: Painless abdominal mass, blood in urine (hematuria), high blood pressure (hypertension), abdominal pain, fever, loss of appetite.

The most characteristic sign of Wilms tumor is a painless, firm mass in the abdomen that parents or caregivers may notice during bathing or dressing their child. This swelling typically appears on one side and may cause the abdomen to look asymmetrical. Hematuria, or blood in the urine, occurs in about 20% of cases and may be visible to the naked eye or detected only through laboratory testing. Hypertension affects approximately 25% of children with Wilms tumor and may be the only initial symptom. Other symptoms can include abdominal discomfort or pain, low-grade fever, nausea, vomiting, and general irritability in younger children. Some children may experience constipation due to the tumor pressing on nearby organs. Weight loss and fatigue may develop as the tumor grows larger.

Causes and risk factors

Wilms tumor arises from genetic changes that occur during kidney development. In about 90% of cases, the tumor develops sporadically with no clear hereditary pattern. However, approximately 10% of cases are associated with genetic syndromes or inherited mutations, particularly in the WT1 gene located on chromosome 11p13. The WT1 gene normally helps control kidney development during fetal growth.

Submit Your Paper
GMJ_Submit_Banner

Several genetic syndromes increase the risk of developing Wilms tumor, including WAGR syndrome (characterized by aniridia, genitourinary abnormalities, intellectual disability, and Wilms tumor), Beckwith-Wiedemann syndrome, and Denys-Drash syndrome. Children with these conditions require regular screening for tumor development. Other risk factors include certain birth defects affecting the genitourinary system, family history of Wilms tumor (though this accounts for only 1-2% of cases), and being of African descent, which shows slightly higher incidence rates.

Prevention

There is no known way to prevent Wilms tumor since most cases occur sporadically without identifiable environmental triggers. However, children with known genetic syndromes that predispose them to Wilms tumor should undergo regular surveillance with abdominal ultrasounds every 3-4 months until age 7-8 years. Genetic counseling is recommended for families with a history of Wilms tumor or associated genetic syndromes to assess risk and discuss screening protocols. Carrier testing and prenatal genetic testing may be available for families with known hereditary forms, though these represent a small minority of cases.

Complications

Without treatment, Wilms tumor can grow rapidly and spread (metastasize) to other organs, particularly the lungs, liver, and lymph nodes. Local complications include compression of nearby organs, leading to breathing difficulties, digestive problems, or urinary obstruction. The tumor may rupture spontaneously or during handling, which can spread cancer cells throughout the abdomen and worsen the prognosis. Hypertension related to the tumor can lead to cardiovascular complications if left untreated. Advanced disease may result in kidney failure, respiratory distress from lung metastases, and ultimately death without appropriate intervention.

Diagnosis

Diagnosis begins with a thorough physical examination and medical history. Imaging studies are crucial and typically include abdominal ultrasound as the initial screening tool, followed by computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen and pelvis to evaluate tumor size, location, and involvement of nearby structures. Chest imaging with CT scan helps identify potential lung metastases.

Laboratory tests include complete blood count, comprehensive metabolic panel, liver function tests, and urinalysis to check for hematuria and assess overall health status. Genetic testing may be recommended, particularly for WT1 gene mutations and chromosomal analysis for associated syndromes. Unlike many other cancers, biopsy is typically not performed before surgery due to the risk of tumor rupture and cell spillage. Instead, diagnosis is often confirmed through surgical removal and subsequent pathological examination of the tumor tissue.

Treatment

Treatment typically involves a multimodal approach combining surgery, chemotherapy, and sometimes radiation therapy. The specific treatment plan depends on tumor stage, histology, and patient age. Surgery aims to completely remove the tumor and affected kidney (nephrectomy) while preserving as much normal kidney function as possible.

Chemotherapy regimens commonly include dactinomycin, vincristine, and doxorubicin. For higher-risk tumors, additional agents such as cyclophosphamide, etoposide, and carboplatin may be used. Treatment protocols differ between North America and Europe, with European approaches often using preoperative chemotherapy to shrink tumors before surgery.

Radiation therapy may be necessary for certain stages of disease or specific histological subtypes. Modern treatment protocols have dramatically improved outcomes while minimizing long-term complications through carefully calibrated dosing and advanced techniques.

Prognosis

The prognosis for Wilms tumor is generally excellent with appropriate treatment. Overall 5-year survival rates range from 90-95%, making it one of the pediatric cancer success stories. Prognosis depends on several factors including tumor stage at diagnosis, histological characteristics, patient age, and response to initial treatment.

Children with favorable histology and early-stage disease have survival rates exceeding 95%. Even children with metastatic disease at diagnosis have cure rates of approximately 85-90% with intensive treatment protocols. The prognosis for anaplastic (unfavorable) histology is somewhat lower but has improved significantly with modern treatment approaches. Long-term survival is often achieved with preserved quality of life, though survivors require ongoing monitoring for potential late effects of treatment.

Quality of life

Most children treated for Wilms tumor go on to lead normal, healthy lives. During treatment, maintaining nutritional status is important, with a balanced diet rich in protein and calories to support healing and growth. Physical activity should be modified during treatment but gradually resumed as tolerated.

School attendance may be interrupted during intensive treatment phases, but educational support services can help maintain academic progress. Emotional support through child life specialists, counselors, or support groups helps children and families cope with the cancer experience. Long-term survivors typically experience normal physical and cognitive development, though regular follow-up care monitors for potential treatment-related effects such as kidney function, heart health, and secondary cancers.

Sleep patterns may be disrupted during treatment but generally normalize afterward. Mental health support remains important throughout the journey, as childhood cancer experiences can have lasting psychological impacts that benefit from professional attention when needed.

Pregnancy and fertility

Fertility is generally preserved in Wilms tumor survivors, though certain chemotherapy agents may pose risks to future reproductive function. Female survivors should discuss pregnancy planning with oncology specialists, as some treatment effects may not become apparent until reproductive years. Most survivors can have successful pregnancies, though they may require enhanced monitoring. Genetic counseling is recommended for survivors planning families, particularly those with hereditary forms of Wilms tumor, to discuss potential risks to offspring.

Children

Since Wilms tumor primarily affects children, pediatric considerations are central to care. Treatment is provided at specialized pediatric cancer centers with multidisciplinary teams including pediatric oncologists, surgeons, nurses, social workers, and child life specialists. Age-appropriate communication about the diagnosis and treatment helps children understand and cope with their experience.

Growth and development monitoring is essential during and after treatment, as both the tumor and its treatment can affect normal childhood development. Educational accommodations may be necessary during treatment, and many hospitals provide schooling services. Family-centered care approaches recognize the impact on siblings and parents, offering comprehensive support services.

When to see a doctor

Seek immediate medical attention if a child develops a noticeable abdominal mass, especially if painless and growing. Other urgent symptoms include blood in urine, persistent abdominal pain, unexplained fever lasting more than a few days, or rapid abdominal swelling.

Routine pediatric care should address any concerns about abnormal abdominal swelling, changes in urination patterns, or unexplained symptoms. Children with known genetic syndromes associated with Wilms tumor should maintain regular surveillance schedules with their healthcare providers.

Regional context

Specific prevalence data for Wilms tumor in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries is limited in published literature. The global incidence appears relatively consistent across populations, though some studies suggest slightly higher rates in certain ethnic groups. We invite healthcare professionals and researchers from these regions to contribute their clinical experience and epidemiological data to enhance our understanding of Wilms tumor patterns in these populations.

Research and clinical trials

Current research focuses on improving outcomes for high-risk patients while reducing treatment toxicity for those with favorable prognosis. Investigations include targeted therapies, immunotherapy approaches, and refined surgical techniques. Studies are exploring the role of specific genetic mutations in treatment planning and prognosis.

Recent breakthroughs include better understanding of tumor biology and identification of new therapeutic targets. Research into late effects of treatment continues to inform long-term survivorship care. Families may find relevant clinical trials through ClinicalTrials.gov, and treatment at specialized pediatric cancer centers often provides access to cutting-edge research protocols.

Frequently asked questions

Can Wilms tumor be cured?

Yes, Wilms tumor has one of the highest cure rates among childhood cancers, with 90-95% of children achieving long-term survival with appropriate treatment.

Will my child need their kidney removed?

Most children with Wilms tumor require surgical removal of the affected kidney (nephrectomy). The remaining kidney typically provides adequate function for normal life.

Is Wilms tumor hereditary?

Most cases (about 90%) are sporadic and not inherited. Only 1-2% of cases show clear hereditary patterns, though some are associated with genetic syndromes.

What are the long-term effects of treatment?

Most survivors experience normal development and health. Potential long-term effects may include kidney function monitoring, heart health surveillance, and screening for secondary cancers, but serious complications are uncommon.

How long does treatment take?

Treatment typically lasts 6-12 months, depending on the stage and risk factors. This includes surgery and chemotherapy, with some children also requiring radiation therapy.

Support and resources

– World Health Organization (WHO): www.who.int
– National Organization for Rare Disorders (NORD): rarediseases.org
– Orphanet: www.orpha.net
– EURORDIS: www.eurordis.org
– Children’s Oncology Group: www.childrensoncologygroup.org
– American Childhood Cancer Organization: www.acco.org

Related conditions

– Beckwith-Wiedemann syndrome
– WAGR syndrome
– Denys-Drash syndrome
– Neuroblastoma
– Rhabdomyosarcoma

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Cite this page

GMJ News Desk. “Wilms tumor.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/wilms-tumor/

CC BY 4.0Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Dual Doctor Couples Face Amplified Childcare Crisis in Medical Training

Dual doctor couples face amplified childcare challenges during medical training, with foundation…

Child Mortality Progress Stalls: 60 Countries Risk Missing 2030 UN Targets

New BMJ analysis reveals 60 countries unlikely to meet UN child survival…

Scientists Discover Master Clock That Controls Biological Growth and Development

Scientists have identified a genetic master clock that controls biological development timing.…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Osteosarcoma

By
Prof. Giorgi Pkhakadze
02/06/2026

Hairy cell leukemia

By
Prof. Giorgi Pkhakadze
02/06/2026

Erdheim-Chester disease

By
Prof. Giorgi Pkhakadze
02/06/2026

Castleman disease

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up